{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:59:53Z","timestamp":1793177993859,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.lungcan.2021.05.034","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T11:37:16Z","timestamp":1622461036000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors \u2013 A nationwide population-based cohort study"],"prefix":"10.1016","volume":"158","author":[{"given":"Hyung Woo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Haak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2021.05.034_bib0005","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S1470-2045(20)30328-4","article-title":"Treatment after progression in the era of immunotherapy","volume":"21","author":"Billan","year":"2020","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2021.05.034_bib0010","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"153","key":"10.1016\/j.lungcan.2021.05.034_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir. Med."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0025","first-page":"1","article-title":"Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases","author":"Inthasot","year":"2019","journal-title":"Acta Clin. Belg."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.034_bib0030","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.034_bib0035","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.034_bib0040","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","article-title":"Immune checkpoint inhibitors and tuberculosis: an old disease in a new context","volume":"21","author":"Langan","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0045","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.2741\/A371","article-title":"Nutritional modulation of host responses to mycobacteria","volume":"3","author":"Dai","year":"1998","journal-title":"Front Biosci"},{"issue":"25","key":"10.1016\/j.lungcan.2021.05.034_bib0050","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.034_bib0055","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00157-2017","article-title":"Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis","volume":"50","author":"Dobler","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.lungcan.2021.05.034_bib0060","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1164\/rccm.200404-512OC","article-title":"Smoking and tuberculosis among the elderly in Hong Kong","volume":"170","author":"Leung","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0065","series-title":"NICE Guideline - Tuberculosis","author":"National Institute for Health and Care Excellence","year":"2016"},{"issue":"12","key":"10.1016\/j.lungcan.2021.05.034_bib0070","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.034_bib0075","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","article-title":"Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma","volume":"55","author":"Lee","year":"2016","journal-title":"Acta Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.034_bib0080","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after Anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0085","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.2147\/OTT.S178246","article-title":"Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report","volume":"11","author":"He","year":"2018","journal-title":"Onco. Ther."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.034_bib0090","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/0284186X.2018.1433877","article-title":"Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer","volume":"57","author":"Jensen","year":"2018","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.034_bib0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.034_bib0100","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa126","article-title":"Incidence of active tuberculosis in lung Cancer patients receiving immune checkpoint inhibitors","volume":"7","author":"Fujita","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105853","article-title":"Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors","volume":"161","author":"Im","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0110","series-title":"Editor (Ed.)^(Eds.), Book Annual Report on the Notified Tuberculosis in Korea","article-title":"Annual report on the notified tuberculosis in Korea, 2019","author":"Korea Centers for Disease Control & Prevention","year":"2019"},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.034_bib0115","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.idc.2010.04.011","article-title":"Tuberculosis in the global aging population","volume":"24","author":"Mori","year":"2010","journal-title":"Infect. Dis. Clin. North Am."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.034_bib0120","first-page":"799","article-title":"Data resource profile: the national health information database of the national health insurance service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.034_bib0125","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J. Korean Med. Sci."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.034_bib0130","doi-asserted-by":"crossref","first-page":"E709","DOI":"10.21037\/jtd.2017.07.31","article-title":"A case of tuberculosis reactivation suspected of cancer progression during oral tyrosine kinase inhibitor treatment in a patient diagnosed as non-small cell lung cancer","volume":"9","author":"Lee","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0135","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2018036","article-title":"Tuberculosis control in the Republic of Korea","volume":"40","author":"Cho","year":"2018","journal-title":"Epidemiol. Health"},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.034_bib0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3414\/ME17-01-0051","article-title":"The charlson comorbidity index in registry-based research","volume":"56","author":"Brusselaers","year":"2017","journal-title":"Methods Inf. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2021.05.034_bib0145","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-directed therapies for infectious diseases: current status, recent progress, and future prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijid.2017.01.028","article-title":"Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm","volume":"56","author":"Rao","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.lungcan.2021.05.034_bib0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in tuberculosis","volume":"31","author":"O\u2019Garra","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.034_bib0160","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.05.034_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019864","article-title":"T cells from programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection","volume":"6","author":"Tousif","year":"2011","journal-title":"PLoS One"},{"issue":"30","key":"10.1016\/j.lungcan.2021.05.034_bib0170","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl_4","key":"10.1016\/j.lungcan.2021.05.034_bib0175","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2021.05.034_bib0180","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The Spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"4 Pt 2","key":"10.1016\/j.lungcan.2021.05.034_bib0185","first-page":"S221","volume":"161","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.034_bib0190","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2021.05.034_bib0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40268-016-0133-0","article-title":"Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms","volume":"16","author":"Srinivas","year":"2016","journal-title":"Drugs R."},{"issue":"6","key":"10.1016\/j.lungcan.2021.05.034_bib0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002824","article-title":"Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries","volume":"16","author":"Campbell","year":"2019","journal-title":"PLoS Med."},{"issue":"8","key":"10.1016\/j.lungcan.2021.05.034_bib0205","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1164\/rccm.201905-0969OC","article-title":"Quantitative IFN-\u03b3 release assay and tuberculin skin test results to predict incident tuberculosis. A Prospective Cohort Study","volume":"201","author":"Gupta","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.lungcan.2021.05.034_bib0210","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01957-2019","article-title":"Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations","volume":"55","author":"Esmail","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"38","key":"10.1016\/j.lungcan.2021.05.034_bib0215","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004919","article-title":"Cancer-specific incidence rates of tuberculosis: a 5-year nationwide population-based study in a country with an intermediate tuberculosis burden","volume":"95","author":"Seo","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.034_bib0220","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12890-020-01351-z","article-title":"Clinical profiles of subclinical disease among pulmonary tuberculosis patients: a prospective cohort study in South Korea","volume":"20","author":"Min","year":"2020","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2021.05.034_bib0225","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1515\/jtim-2016-0011","article-title":"A little help from steroids in oncology","volume":"4","author":"Lossignol","year":"2016","journal-title":"J. Transl. Int. Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221004141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:54:29Z","timestamp":1759236869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221004141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":45,"alternative-id":["S0169500221004141"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.034","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors \u2013 A nationwide population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.05.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}